Poland· PL-100490995
Ultomiris
A ravulizumab product containing ravulizumabum, registered in Poland by Alexion Europe SAS.
Checked against URPL (Poland) on
Informational only — not a medical device.
The record
At a glance
URPL (Poland)- Active substance
- Ravulizumabum
- Manufacturer
- Alexion Europe SAS
- Country
- Poland (PL)
- ATC code
- L04AA43
- ATC class
- Ravulizumab
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
2 interactions on record for ravulizumab.
Graded by severity as the source publishes them — 2 minor. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ravulizumab · interactions on record
2 records
Same medicine, other countries
Ravulizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumUltomiris 245 mgAlexion Europe
- SwedenUltomiris 245 mg Injektionsvätska, lösningAlexion Europe SAS
- FinlandUltomirisAlexion Europe SAS
- CzechiaULTOMIRISAlexion Europe SAS, Levallois-Perret
- United KingdomUltomiris 1,100mg/11ml concentrate for solution for infusion vialsAlexion Pharma UK Ltd
- United StatesUltomirisAlexion Pharmaceuticals Inc.
- CanadaULTOMIRISALEXION PHARMA GMBH
- SwitzerlandUltomiris 1100 mg/11 ml, Konzentrat zur Herstellung einer InfusionslösungAlexion Pharma GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Ultomiris
- Liechtenstein · Ultomiris
- Norway · Ultomiris
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/63c8ca5f-3865-4384-9cb9-4ccbea28abf1 GET /v1/drugs/63c8ca5f-3865-4384-9cb9-4ccbea28abf1?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań we wkładzie",
"source": "urpl",
"strength": "245 mg",
"packaging": "Rpz ¦ EU/1/19/1371/004 ¦ 152412\n1 wkład ¦ 1 wstrzykiwacz 3,5 ml",
"substance": "Ravulizumabum 245 mg",
"common_name": "Ravulizumabum",
"pl_product_id": "100490995",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about ravulizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.